Menu UF Health Home Menu

Thomas J. George Jr., MD

Thomas J. George Jr., MD, FACP
Associate Professor of Medicine
Director, Gastrointestinal Oncology Program
Research Director, Joint Oncology Program (UFHCC & UFHCC-Orlando Health)

PO Box 100278
Gainesville, FL 32610-0278

TEL: (352) 273-7832
FAX: (352) 273-7849


Dr. George is a clinical investigator and educator with a focus on gastrointestinal malignancies. He is board certified in Medical Oncology. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, and numerous clinical trial cooperative groups.




MD University of Florida Medicine
Residency University of Florida Internal Medicine
Fellowship University of Florida Hematology & Oncology

Academic/Research Interests:

Clinical research in gastrointestinal malignancies is a primary aspect of Dr. George’s academic interests. Specific areas of focus include active participation and development of clinical trials to promote novel drug application in patient care, quality of life/cancer care decision making, and identification of predictive markers for individualized therapy. He serves as a Gubernatorial appointee and Chair of the Florida Cancer Control and Research and Advisory Council which advises the legislature on matters related to cancer care and research in the state. Educationally, he is a dedicated mentor and teacher of fellows, residents, and students in the College of Medicine and is actively involved in Graduate Medical Education administration and policy development at a local and national level.

  • Experimental Therapeutics
    Dr. George is involved as a Principle Investigator in numerous clinical trials aimed at determining the optimal treatment for patients with gastrointestinal malignancies.  Collaboration includes numerous national clinical trial groups as well as the University of Florida Proton Therapy Institute.  Representative protocols include studies in colon, rectal, pancreatic and hepatobiliary cancers. These novel therapies involving personalized therapeutics hold the promise of becoming the next breakthrough in cancer patient care.
  • Personalized Oncology
    As cancer care becomes more complex, focus on a tailored approach to individualized treatments which maximize benefit while minimizing risk is critical.  Research involving the identification of specific markers or elements of a patient or their cancer which will predict, in advance, response to a given therapy is an area of active investigation.  The incorporation of new molecular markers, gene expression profiling, and pharmacogenomics into clinical care will help to provide patients with truly personalized care.
  • Quality of Life and Decision Making
    Patients and their loved ones facing the new diagnosis of a cancer face a variety of potentially overwhelming treatment options and decisions.  Collaboration with behavioral scientists, clinical psychologists, and others are helping to break down the complex process of decision making in an attempt to determine how best to deliver treatment options and maximize quality of life.
  • Educating the Next Generation of Oncologists
    The next generation holds the keys to continuing the work currently ongoing in cancer biology, therapeutics, and patient care.  Development of novel educational tools, training modules, and advanced curricula aimed at providing these oncologists-in-training with the skills needed to practice state of the art medicine while maintaining the humanism and sensitivity required for being entrusted with the honor of caring for patients with cancer is an area of ongoing professional and research interest.

Clinical Interests:

  • Colorectal cancer
  • Esophageal & stomach cancer
  • Liver metastases
  • Pancreatic & biliary cancers
  • Pancreatic islet cell tumor
  • Experimental treatments


  • Marsh R and George T.  Rationale and Appropriate Use of Chemotherapy and Radiation Therapy for Pancreatic Ductal adencarcinoma.  Current Gastroenterology Reports. 2006 Apr;8(2):111-20
  • George TJ Jr.  KRAS Mutational Analysis:  Ready for Prime Time?  Community Oncology.  2008 Aug;5(8):433-6
  • George TJ Jr.  Welcome to the Team:  Trastuzumab in Her2 Positive Esophagogastric Cancers.  Community Oncology.  2009 Dec;6(12):543-5.
  • George TJ Jr, LaPlant KD, Walden EO, Davis AB, Riggs CE, Close JL, George SN, Lynch JW.  Managing Cetuximab Hypersensitivity-Infusion Reactions:  Incidence, Risk Factors, Prevention, and Retreatment.  J Support Oncol. 2010 Mar-Apr;8(2):72-7
  • George TJ Jr, Siddiqui T, Mendenhall W, Zlotecki R, Grobmyer S, Hochwald S, Rout R, Chang M, Larson B, King J.  A Phase II Trial of Neoadjuvant Capecitabine Combined with Hyperfractionated Accelerated Radiation Therapy in Locally Advanced Rectal Cancer.  Am J Clin Oncol. 2010 Jun 33(3):251-6
  • Allegra CJ, George TJ Jr, Yothers G.  Multi-agent Regimens for Metastatic Colorectal Cancer:  If Some is Good, More Must be Better.  J Natl Cancer Inst. 2011 Jan 5;103(1):4-5
  • Lin SH, George TJ, Ben-Jesef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung C.  Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy.  Accepted by J Natl Cancer Inst.

Please click here for a list of Dr. George’s industry relationships.